On Thursday, Oil States International, Inc. (NYSE:OIS)’s shares declined -5.49% to $40.25.
Oil States International, Inc. (OIS) stated that a combination of factors, counting the continued decrease in the U.S. land drilling rig count, certain customers drilling wells but electing not to complete them, reduced pricing for certain completion service offerings and the recent heavy rainfall across Texas and Oklahoma have negatively influenced results for its well site services segment during the second quarter of 2015. These factors have caused Oil States to revise its second quarter 2015 guidance lower for its well site services segment. Revenues for the segment are now predictable to range from $85 million to $90 million with EBITDA margins averaging 13% to 14%. This compares to prior second quarter guidance given on April 30, 2015 for well site services revenues of $110 million to $120 million with EBITDA margins averaging 19% to 21%.
Oil States International, Inc., through its auxiliaries, provides specialty products and services to oil and natural gas companies worldwide. It operates through two segments, Offshore Products and Well Site Services. The Offshore Products segment designs, manufactures, fabricates, inspects, assembles, repairs, tests, and markets subsea equipment and offshore vessel and rig equipment.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s shares gained 9.90% to $14.48.
BioCryst Pharmaceuticals, Inc. (BCRX) declared that executives from BioCryst are planned to provide a corporate summary and update regarding the Company’s programs at the JMP Securities Life Sciences Conference in New York on Tuesday, June 23, 2015 at 3:30 p.m. Eastern Time.
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its product candidates comprise peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza; BCX4161, an oral serine protease inhibitor, which is in Phase II clinical trial for hereditary angioedema (HAE); and BCX7353 and other second generation HAE compounds, which are oral serine protease inhibitors that are in preclinical trial for HAE.
At the end of Thursday’s trade, Banro Corporation (USA) (NYSEMKT:BAA)‘s shares surged 2.50% to $0.357.
Banro Corporation (USA) (BAA) hereby notifies holders of Series A Preference Shares of Banro (“Banro Series A Shares”) and holders of Preferred Shares of Banro Group (Barbados) Limited (“Barbados Preferred Shares”) of the following information necessary to calculate the amount of dividends payable on such shares. This information is being offered in accordance with the terms of such shares. Defined terms in this press release which are not otherwise defined shall have the meaning given to them in the articles of Banro and Banro Group (Barbados) Limited (“Barbados Subco”).
- The simple average of the Reference Gold Price during the three-month period ending on March 31, 2015 is US$1,218.
- The Relevant Number for the purposes of the calculation of the Dividend Liquidation Preference is 0.017501.
- There are presently no dividends accrued and unpaid on the Banro Series A Shares or the Barbados Preferred Shares.
- The Monthly Production Level for the first quarter of 2015 was 15,066 ounces of gold per month, such that the Annual Dividend Yield is 14%.
If, as and when dividends are authorized and declared by Banro and Barbados Subco in respect of the June 30, 2015 Dividend Payment Date, the dividend payable per Banro Series A Share and Barbados Preferred Share will be US$0.75.
Banro Corporation, together with its auxiliaries, engages in the exploration, development, and production of mineral properties. It primarily explores for gold. The company holds a 100% interest in 4 gold properties, counting Twangiza, Namoya, Lugushwa, and Kamituga comprising 13 exploitation permits that cover an area of about 2,612 square kilometers in the South Kivu and Maniema provinces of the Democratic Republic of the Congo. It also owns 14 exploration permits covering an area of about 2,638 square kilometers located between the Twangiza and Namoya properties.
Health Care REIT, Inc. (NYSE:HCN), ended its Thursday’s trading session with 0.95% gain, and closed at $68.88.
Health Care REIT, Inc. (HCN) and Revera, Inc. declared that they have reached a definitive agreement to acquire Regal Lifestyle Communities Inc. (“Regal”) (RLC.TO) through an existing 75/25 joint venture (JV) for CAD$12.00 per share in cash, or a total enterprise value of about CAD$766 million, or US$623 million. The initial cash yield is anticipated to be 6.1% and anticipated to be right away accretive to FFO and FAD per share. All currency references are based upon an exchange rate of CAD to USD of 1.23:1.
Regal is a publicly traded Canadian corporation that owns and operates 23 high-quality seniors housing communities with over 3,600 units. This private pay portfolio comprises 13 communities in Ontario, seven in Quebec, and one each in British Columbia, Saskatchewan and Newfoundland. About 83% of the portfolio’s net operating income is derived from Toronto, Montreal, Ottawa and Vancouver.
Health Care REIT, Inc. is an independent equity real estate investment trust. The firm engages in acquiring, planning, developing, managing, repositioning and monetizing of real estate assets. It primarily invests in the real estate markets of the United States. The firm primarily invests in senior living and health care properties.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
